Overview

Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe pediatric Crohn's Disease response to sargramostim in patients with or without steroid therapy at two possible dosage levels.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Molgramostim
Sargramostim